

**From:** [Jarvis, Candace](#)  
**To:** [James L'Italien, PhD \(jlitalien@avexis.com\)](#)  
**Cc:** [Nancy Boman](#); [Whatley, Angela](#); [Byrnes, Andrew](#); [Jarvis, Candace](#)  
**Subject:** BLA 125694/0 | AveXis, Inc | Information Request 36  
**Date:** Monday, February 25, 2019 8:46:59 AM **Attachments:**  
[image013.png](#)

---

Good morning Dr L'Italien,

We have the following request for information regarding BLA 125694. Please respond to this request asap.

During the Mid-cycle communications meeting held on January 29, 2019 AveXis stated they are updating the process validation sections of the BLA and would provide additional support, data and explanation for the manufacturing process operating ranges by February 15 2019. Please let us know when you plan to submit this information.

Please acknowledge receipt of this request.

*Regards,*

*Candace N. Jarvis*  
*Regulatory Project Manager*  
*Center for Biologics Evaluation and Research*  
**Office of Tissues and Advanced Therapies**  
**U.S. Food and Drug Administration**  
Tel: 240-402-8315  
[candace.jarvis@fda.hhs.gov](mailto:candace.jarvis@fda.hhs.gov)



THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.